Immutep Limited

29/07/2025

Immutep Limited today announces an upcoming poster presentation for the pivotal TACTI-004 (KEYNOTE-F91) Phase III trial at the IASLC 2025 World Conference on Lung Cancer (WCLC), taking place in Barcelona, Spain, from the 6th - 9th of September 2025.

The poster presentation will include an overview and study design of the TACTI-004 Phase III trial evaluating efti in combination with ’s KEYTRUDA® (pembrolizumab) and chemotherapy as first line therapy for patients with advanced or metastatic non-small cell lung cancer.

The poster will be available on the Posters & Publications section of Immutep’s website following the presentation.

Find more details to the presentations here: http://bit.ly/4opytYm

29/07/2025

Immutep Limited is pleased to share that three abstracts for clinical trials evaluating its first-in-class MHC Class II agonist, efti, have been accepted for presentation at the ESMO - European Society for Medical Oncology Congress 2025 taking place from the 17th - 21st of October in Berlin, Germany.

Details of the presentations are as follows:
- An abstract on the Company’s pivotal TACTI-004 Phase III in 1L NSCLC has been accepted for a Trials in Progress ePoster
- A Proffered Paper oral presentation detailing results from EFTISARC-NEO, a Phase II investigator-initiated trial in resectable soft tissue sarcoma
- A poster presentation detailing data from the INSIGHT-003 Phase I investigator-initiated trial in first-line non-small cell lung cancer (1L NSCLC)

Abstracts will be made available on the ESMO website on 13 October 2025.

Find more details to the presentations here: http://bit.ly/4ogExCu

14/07/2025

Immutep Limited's CEO Marc Voigt appeared on ShareCafe’s latest episode of Table for Two, where he shared clinical trial updates across Immutep’s oncology and autoimmune programs.

Marc discusses the results from the TACTI-003 and INSIGHT-003 trials in head & neck cancer and in non-small cell lung cancer, as well as exciting progress on IMP761 - a first-in-class LAG-3 agonist antibody targeting autoimmune diseases.

Additionally, he highlights TACTI-004, Immutep's pivotal Phase 3 trial in non-small cell lung cancer, and outlines key upcoming milestones for the Company through year end 2025 and beyond.

Watch the full episode here:

Immutep (ASX:IMM) CEO Marc Voigt shares promising clinical trial updates across the company’s oncology and autoimmune programs.In head and neck cancer, the TACTI-003 trial has shown a median overall survival of 17.6 months—more than double the typical 7–8 months—and a much lower rate of seri...

23/06/2025

Immutep Limited announces positive initial efficacy data & continued favourable safety from first-in-human Phase I evaluating IMP761, a first-in-class agonist antibody. The substantial reduction in T cell activity at 0.9mg/kg dosing level highlights the potential efficacy of IMP761 in treating .

Dosing will continue at 2.5mg/kg and higher levels, with additional data to follow in 2H’CY2025.

Read more: http://bit.ly/3TA8fUF

02/06/2025

Immutep Limited is participating in the upcoming Jefferies Global Healthcare Conference in NYC. CEO Marc Voigt will present a company overview on Thurs, June 5th at 11:40am ET (US).

A live webcast and replay of the presentation will be available here: https://wsw.com/webcast/jeff319/immp/1860168

25/05/2025

Immutep Limited is pleased to report the investigator-initiated EFTISARC-NEO Phase II trial evaluating efti with and KEYTRUDA in (STS) has met its primary endpoint. STS is an orphan disease with high unmet medical need.

Detailed study results are planned for presentation at a medical conference later this year from the trial’s investigators at the Maria Sklodowska-Curie National Research Institute of Oncology.

Read more here https://bit.ly/4k48nYa

15/05/2025

Immutep Limited has reported excellent survival data from the investigator-initiated INSIGHT-003 trial aimed at treating advanced non-small cell lung cancer (NSCLC).

The trial reported a 60.8% response rate and 90.2% disease control rate in patients, according to RECIST 1.1. This data demonstrates significant improvement in response rate compared to historical controls and safety continues to be favorable.

Additional data from INSIGHT-003 is expected to be presented at a medical conference in 2025 and beyond.

Read more: https://bit.ly/4j70mk1

07/05/2025

Immutep Limited reported excellent survival data from the TACTI-003 Phase IIb trial: a median overall survival period of 17.6 months for head and neck cancer patients (PD-L1 CPS

22/01/2025

We're pleased to announce patient enrolment has been completed for the EFTISARC-NEO trial in soft tissue sarcoma.

The Phase II trial is evaluating Immutep Limited's efti in combination with radiotherapy plus KEYTRUDA® (pembrolizumab) and is being conducted by the Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw. Further data from the trial is expected in 2025.



Read the ASX announcement: https://bit.ly/3E1Zv5f

20/01/2025

Thank you to everyone who took the time to meet with Immutep Limited last week at the 43ʳᵈ Annual J.P. Morgan Healthcare Conference.

It was a busy week for our team!

06/09/2024

Immutep Limited (ASX: IMM) is delighted to be joining the esteemed S&P/ASX 300 Index. Being part of the marks the Company's considerable growth and progress over the years, as well as enhancing its market visibility and supporting investor confidence.

Many thanks to our fantastic team and shareholders who share our excitement for the journey ahead for our LAG-3 therapeutics in cancer and autoimmune disease.

20/08/2024

Immutep Limited is excited to announce its late-breaking abstract has been accepted and selected as a Proffered Paper oral presentation at the 2024 ESMO - European Society for Medical Oncology Congress in Barcelona, Spain.

Claus Andrup Kristensen, MD, PhD, Head of Section for Thoracic and Head and Neck Oncology will present on Sunday 15 September at 10:25–10:35am CET.

Please click here to read full announcement: https://bit.ly/3XbAdJ9